UNCY · Unicycive Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $675.0K | $951.0K | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $9.12M | $20.01M | $12.90M | $12.44M | $1.01M |
| SG&A | $20.40M | $12.10M | $8.55M | $383.0K | $58.0K |
| Total Operating Expenses | $29.52M | $32.12M | $21.45M | $19.00M | $2.02M |
| D&A | $34.0K | $22.0K | $9.0K | $428.0K | $63.0K |
| Operating Income | ($29.52M) | ($32.12M) | ($20.77M) | ($18.05M) | ($2.02M) |
| Interest Expense | $71.0K | $71.0K | $82.0K | $6.0K | $244.0K |
| Income Tax | - | - | - | - | - |
| Net Income | ($26.55M) | ($36.73M) | ($30.54M) | ($18.06M) | ($2.26M) |
| EPS - Basic | ($1.67) | ($5.60) | ($12.80) | ($12.00) | ($2.70) |
| EPS - Diluted | ($1.67) | ($5.60) | ($12.80) | ($12.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $29.20M | $26.14M | $9.70M | $455.0K | $16.58M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | $2.19M | - |
| Accounts Payable | $383.0K | $1.06M | $839.0K | $892.0K | $742.0K |
| Current Assets | $48.96M | $30.95M | $13.40M | $2.64M | $18.41M |
| Total Assets | $49.13M | $31.67M | $14.19M | $2.82M | $18.74M |
| Current Liabilities | $18.94M | $24.12M | $17.53M | $3.28M | $2.10M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $18.94M | $24.24M | $18.00M | $3.28M | $2.26M |
| Stockholders' Equity | $30.20M | $7.43M | ($3.81M) | ($466.0K) | $16.48M |
| Retained Earnings | ($127.83M) | ($101.27M) | ($64.54M) | ($34.00M) | ($15.94M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($31.32M) | ($28.57M) | ($18.28M) | ($15.65M) | ($1.46M) |
| Investing Cash Flow | ($12.10M) | ($72.0K) | ($12.0K) | ($2.0K) | ($29.0K) |
| Financing Cash Flow | $46.47M | $45.09M | $27.54M | ($471.0K) | $1.44M |
| CapEx | $24.0K | $72.0K | $12.0K | $29.0K | - |
| Free Cash Flow | ($31.34M) | ($28.65M) | ($18.30M) | ($15.68M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | -3077.6% | -1898.2% | - |
| EBITDA margin | - | - | -3076.3% | -1853.2% | - |
| Net margin | - | - | -4525.0% | -1898.8% | - |
| Free cash flow margin | - | - | -2710.4% | -1648.8% | - |
| FCF / Net income | 1.18 | 0.78 | 0.60 | 0.87 | - |
| R&D / Revenue | - | - | 1911.4% | 1307.7% | - |
| SG&A / Revenue | - | - | 1266.2% | 40.3% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -54.0% | -116.0% | -215.2% | -640.8% | -12.1% |
| Return on equity | -87.9% | -494.3% | 801.9% | 3875.1% | -13.7% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 |
| Quick ratio | 2.59 | 1.28 | 0.76 | 0.14 | 8.75 |
| Cash ratio | 1.54 | 1.08 | 0.55 | 0.14 | 7.88 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -415.7x | -452.4x | -253.3x | -3008.7x | -8.3x |
| Equity multiplier | 1.63 | 4.26 | -3.73 | -6.05 | 1.14 |
| Liabilities / Assets | 0.39 | 0.77 | 1.27 | 1.17 | 0.12 |
| Efficiency | |||||
| Asset turnover | - | - | 0.05 | 0.34 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 3.0x | 71.6x | - | - | - |
| P / S | - | - | 315.6x | 85.5x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | -29.0% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 8.1% | -54.6% | -15.1% | -793.7% | - |
| Net income growth (YoY) | 27.7% | -20.2% | -69.1% | -697.6% | - |
| EPS growth (YoY) | 70.2% | 56.2% | -6.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -9.4% | -56.6% | -16.7% | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 306.4% | - | -717.4% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Unicycive Therapeutics against the 5 most active filers in the same SIC group.